Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXG LexaGene	C$0.11 -19.2%	C$0.11	C$0.07 ▼ C$0.31	C$14.77M	2.26	170,061 shs	2.14 million shs
ONC Oncolytics Biotech	C$1.44 -2.0%	C$1.44	C$1.20 ▼ C$4.49	C$108.61M	1.49	80,832 shs	31,075 shs
PTN Palatin Technologies	$1.89 +1.1%	$0.00	$1.43 ▼ $5.65	$30.18M	0.93	850,734 shs	232,261 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXG LexaGene	0.00%	0.00%	0.00%	0.00%	0.00%
ONC Oncolytics Biotech	-2.04%	-8.28%	+1.41%	-8.86%	-4.64%
PTN Palatin Technologies	0.00%	-2.67%	+18.18%	-54.27%	-31.32%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXG LexaGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	0.5637 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.0	0.0
PTN Palatin Technologies	2.0002 of 5 stars	3.5	2.0	0.0	0.0	2.6	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXG LexaGene	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	3.00	Buy	C$6.00	316.67% Upside
PTN Palatin Technologies	3.00	Buy	$17.00	799.47% Upside

Current Analyst Ratings

Latest PTN, ONC, and LXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00
2/28/2024	PTN Palatin Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $17.00
2/15/2024	PTN Palatin Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXG LexaGene	C$110.93K	133.13	C$0.00 per share	21.25	C$0.01 per share	10.50
ONC Oncolytics Biotech	N/A	N/A	C$0.34 per share	4.22	C$0.37 per share	N/A
PTN Palatin Technologies	$4.85M	6.29	N/A	N/A	$0.01 per share	189.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXG LexaGene	-C$8.54M	-C$0.08	N/A	∞	N/A	N/A	-339.54%	-120.21%	N/A
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)
PTN Palatin Technologies	-$27.54M	-$2.58	N/A	N/A	N/A	-445.12%	-583.06%	-184.90%	5/14/2024 (Estimated)

Latest PTN, ONC, and LXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A
2/14/2024	Q2 24	PTN Palatin Technologies	-$0.20	-$0.56	-$0.36	-$0.56	$2.28 million	$2.03 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXG LexaGene	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
PTN Palatin Technologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXG LexaGene	138.01	1.39	1.13
ONC Oncolytics Biotech	1.54	9.01	8.86
PTN Palatin Technologies	N/A	1.09	1.09

Ownership

Institutional Ownership

Company	Institutional Ownership
LXG LexaGene	0.09%
ONC Oncolytics Biotech	6.98%
PTN Palatin Technologies	11.50%

Insider Ownership

Company	Insider Ownership
LXG LexaGene	17.85%
ONC Oncolytics Biotech	6.24%
PTN Palatin Technologies	7.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
LXG LexaGene	41	140.64 million	N/A	Not Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable
PTN Palatin Technologies	34	16.14 million	14.89 million	Not Optionable

PTN, ONC, and LXG Headlines

Source	Headline
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Buys $12,720.00 in Stock americanbankingnews.com - April 14 at 5:26 AM
	Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying msn.com - April 12 at 10:36 AM
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Purchases $12,720.00 in Stock insidertrades.com - April 12 at 6:56 AM
	Palatin Technologies (NYSEAMERICAN:PTN) Shares Pass Above 200-Day Moving Average of $0.00 americanbankingnews.com - April 10 at 3:22 AM
	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study zacks.com - April 9 at 10:01 AM
	Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643 marketwatch.com - April 8 at 1:18 PM
	Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data finance.yahoo.com - April 8 at 1:18 PM
	Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers msn.com - April 8 at 10:21 AM
	Palatin stock jumps 16% on positive Phase 3 data for eye drug msn.com - April 8 at 10:12 AM
	Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive markets.businessinsider.com - April 8 at 8:18 AM
$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 finance.yahoo.com - April 8 at 8:18 AM
	Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Robert K. Deveer, Jr. Sells 11,700 Shares insidertrades.com - March 17 at 8:52 AM
	PTN Apr 2024 2.500 put finance.yahoo.com - March 15 at 10:53 PM
	PTN Apr 2024 7.500 call finance.yahoo.com - March 15 at 10:53 PM
	Palatin files to sell 1.92M shares of common stock for holders msn.com - March 14 at 7:20 PM
	Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects markets.businessinsider.com - February 29 at 3:20 PM
	Palatin to tweak second PL-9643 phase III in dry eye disease bioworld.com - February 28 at 7:51 PM
	Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX) markets.businessinsider.com - February 28 at 5:21 PM
	Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK) markets.businessinsider.com - February 28 at 2:50 PM
	Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary endpoint miss fiercebiotech.com - February 28 at 12:20 PM
	Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets msn.com - February 28 at 12:20 PM
	Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) finanznachrichten.de - February 28 at 9:49 AM
	Palatin Technologies Shares Tumble Premarket on Dry-Eye Study Results marketwatch.com - February 28 at 9:49 AM
	Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) finance.yahoo.com - February 28 at 8:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
April 2, 2024 11:25 AM
View Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
April 5, 2024 8:45 AM
View Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?
March 26, 2024 7:00 AM
View Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?
Cannabis: One Stock to Play the Movement
April 8, 2024 8:38 AM
View Cannabis: One Stock to Play the Movement

All Headlines

Company Descriptions

LexaGene

CVE:LXG

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Palatin Technologies

NYSEAMERICAN:PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial